Our Team



Douglas Crawford

Douglas Crawford, PhD

General Manager, QB3@953
Managing Director, Mission Bay Capital

Douglas Crawford’s goal is to help entrepreneurial scientists create successful startups. To this end, Doug and his colleagues have systematically lowered the barriers between great ideas and successful companies. For instance, Crawford created and manages QB3@953. This state-of-the-art co-working laboratory program in San Francisco allows entrepreneurs to rapidly generate data without getting bogged down in facility management. Rather than spending months getting a facility up and running, QB3@953 startups can generate important data in their first week.

In the first 3 years, this program has helped launch 94 companies that have raised over 1.36B. This incubator program reflects Doug’s passion for startups and his eagerness to help entrepreneurs overcome challenges.

Doug is also the Managing Director of Mission Bay Capital and has overseen the investment in 34 companies, 4 of which have already enjoyed successful exits (Calithera, iPierian, Redwood Biosciences and Zephyrus). He is a board member of Avexegen, Circle Pharma, Delpor, Invenio, Magnamosis, Magnap, SiteOne (observer), Tangible Sciences, and Viewpoint.

Crawford received his PhD in biochemistry from UCSF. Loves traveling with his family, making great pizza, and killer cappuccinos.

Robert Blazej

Robert Blazej, PhD

Director, QB3@953
Principal, Mission Bay Capital

Robert is a passionate biotechnologist with a diverse skillset spanning business, life science, engineering and intellectual property. Robert Blazej brings 10 years of operational experience both as a successful entrepreneur and as a leader within an international corporation.

For the previous four years, Robert directed Novozymes’ Digital Biotechnology unit in San Francisco and their global biotechnology scouting team. Previously, Robert was CEO of Allopartis Biotechnologies, a company he co-founded with the vision that mircrodoplets would transform the scale and pace of life science research. Allopartis was acquired by Novozymes in 2013.

Robert earned his Ph.D. in 2006 in Bioengineering jointly from UC Berkeley and UC San Francisco. His graduate research focused on the design, implementation and characterization of microfluidic systems for next-generation DNA sequencing. Blazej is a published contributor to the human, drosophila, and canine genome projects, with his work on integrated microfluidic DNA sequencing featured on the cover of PNAS and in Nature.

Linda Eng

Linda Eng

Business Manager, QB3@953
Office Manager, Mission Bay Capital

Linda Eng is Business Manager for QB3@953, managing space and lease interactions, application processes, and facilities. Linda is also the Office Manger for Mission Bay Capital, helping the venture team track investment deals, organize meetings, and provide administrative support.

She served as assistant to Douglas Crawford at QB3 years ago, where she helped Mission Bay Capital in its formation and launch. Thereafter, Linda was offered a role within UCSF’s Department if hematology and oncology as Program Manager of the Translational Research Program under the Alliance for Clinical Trials in Oncology, an NCI cooperative group. She managed the requests, approval process, and regulatory requirements for translational studies of biospecimens from all tumor types from the Alliance’s federated biorepositories. While there, her role grew into Program Manager of the Prostate Cancer Research Program for UCSF’s Helen Diller Family Comprehensive Cancer Center. Linda provided project management for a $10M Stand Up To Cancer Prostate Dream Team, a six-institution clinical trial effort to target treatment-resistant metastatic prostate cancer.

Linda enjoys reading, science fiction movies, British TV, time with family, and traveling.

Our Team: Anna Wong, Linda Eng, Michael Munchua, Douglas Crawford, Antonio Solano, Fred Dizon, and Emma Matillano

qb3at953 News

Upcoming Event

  • Capitalizing on New Trends of Chinese Investments in the U.S. and Navigating Legal Issues for Startups in China

    Karen Wong, PhD, Partner Wilson Sonsini Goodrich & Rosati RSVP The rapid growth of the healthcare market in China is fueling many Chinese funds and pharmaceutical companies to invest in healthcare companies in the US and to attract talent to set up companies in China. This presents an unprecedented cross-border environment and new business opportunities for Bay Area entrepreneurs. Please join us for a lively and hands-on discussion with Dr. Karen Wong, a partner of Wilson Sonsini Goodrich & Rosati, to learn about real-life stories, opportunities, and pitfalls in setting up startups with planned growth or commercialization in China. Karen will cover the topics of US-China cross-border deal structures, technology transfer and licensing, fundraising and term-sheet negotiation, and patent filing strategies for both the US and China markets. Dr. Karen Wong has a wealth of experience in life sciences patent preparation and prosecution, technology transfer and licenses, and due-diligence studies in connection with VC financing, M&A, and public offering. Dr. Karen Wong has served as IP counsel to many venture-backed companies in the US and in China, and has worked on numerous major cross-border transactions, strategic alliance transactions, acquisitions, spin-outs, and IPOs. Karen is fluent in Mandarin, Cantonese, and Sichuan dialect.


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter